Соединенные Штаты - английский - NLM (National Library of Medicine)

blenheim pharmacal, inc. - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 500 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin tablets and other antibacterial drugs, levofloxacin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. levofloxacin tablets are indicated for the treatment of adults (≥ 18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. culture and susceptibility testing appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see mi

Соединенные Штаты - английский - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 500 mg - levofloxacin tablets are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. levofloxacin tablets are indicated for the treatment of nosocomial pneumonia due to methicillin-susceptible staphylococcus aureus, pseudomonas aeruginosa, serratia marcescens, escherichia coli, klebsiella pneumoniae, haemophilus influenzae, or streptococcus pneumoniae. adjunctive therapy should be used as clinically indicated. where pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see clinical studies (14.1)]. levofloxacin tablets are indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible staphylococcus aureus, streptococcus pneumoniae (including multi-drug-resistant streptococcus pneumoniae [mdrsp]), haemophilus influenzae, haemophilus parainfluenzae, klebsiell

Соединенные Штаты - английский - NLM (National Library of Medicine)

unit dose services - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 750 mg

Ирландия - английский - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - levofloxacin hemihydrate - film coated tablet - 500 base milligrams

Ирландия - английский - HPRA (Health Products Regulatory Authority)

rowex ltd - levofloxacin - film coated tablet - 500 milligram

Ирландия - английский - HPRA (Health Products Regulatory Authority)

rowex ltd - levofloxacin - film coated tablet - 250 milligram

Ирландия - английский - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - levofloxacin hemihydrate - film coated tablet - 500 base milligrams

Ирландия - английский - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - levofloxacin - solution for infusion - 5 mg/ml - fluoroquinolones

Ирландия - английский - HPRA (Health Products Regulatory Authority)

pharmathen s.a. - levofloxacin hemihydrate - film coated tablet - 250 milligram - fluoroquinolones

Ирландия - английский - HPRA (Health Products Regulatory Authority)

pharmathen s.a. - levofloxacin hemihydrate - film coated tablet - 500 milligram - fluoroquinolones